[212pb]vmt-α-net,
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2023 (NCT05636618)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
- Payload
- 212-lead
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06148636 | Early Phase 1 (Phase 1) | Nov 10, 2023 | IsoRay Medical, Inc., National Cancer Institute (NCI), University of Iowa |
| NCT05636618 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2023 | Viewpoint Molecular Targeting |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IsoRay Medical, Inc. | For profit | 1 | 0 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| University of Iowa | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Viewpoint Molecular Targeting | For profit | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1